web statistics
PRESS ROOM        PUBLICATIONS       CAREERS
KineMed  ► 
Our unique window into living biology is revolutionizing pharma R&D programs and generating comprehensive drug-diagnostic solutions for improved disease management
Find out more


Latest News

KineMed and U.S. Army Announce Collaboration to Measure Muscle Func...
KineMed and U.S. Army Announce Collaboration to Measure Muscle Function and Response During Military Operations
10/28/2014 1:00:00 AM

KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters.

KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurod...
KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurodegenerative Disease at the 8th Annual Neurodegenerative Conditions Research & Development Conference 
9/17/2014 1:00:00 AM

KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, will give a presentation titled “Translatable Dynamic Biomarkers: The Future of Biomarkers in Neurodegenerative Diseases” at the 8th Annual Neurodegenerative Conditions Research & Development Conference. The presentation will take place on Friday, September 19th, from 12:55‐1:20 p.m. PDT at the Sheraton Fisherman's Wharf Hotel San Francisco, California as part of the session titled “Biomarkers: Translation from Discovery to Clinical.”

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, ...
KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy
9/4/2014 1:00:00 AM

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

Latest News

KineMed and U.S. Army Announce Collaboration to Measure Muscle Func...
KineMed and U.S. Army Announce Collaboration to Measure Muscle Function and Response During Military Operations
10/28/2014 1:00:00 AM

KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters.

KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurod...
KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurodegenerative Disease at the 8th Annual Neurodegenerative Conditions Research & Development Conference 
9/17/2014 1:00:00 AM

KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, will give a presentation titled “Translatable Dynamic Biomarkers: The Future of Biomarkers in Neurodegenerative Diseases” at the 8th Annual Neurodegenerative Conditions Research & Development Conference. The presentation will take place on Friday, September 19th, from 12:55‐1:20 p.m. PDT at the Sheraton Fisherman's Wharf Hotel San Francisco, California as part of the session titled “Biomarkers: Translation from Discovery to Clinical.”

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, ...
KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy
9/4/2014 1:00:00 AM

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

Latest News

KineMed and U.S. Army Announce Collaboration to Measure Muscle Func...
KineMed and U.S. Army Announce Collaboration to Measure Muscle Function and Response During Military Operations
10/28/2014 1:00:00 AM

KineMed, Inc. and the U.S. Army Research Institute of Environmental Medicine’s (USARIEM) Military Nutrition Division announced today they are entering into a partnership to examine KineMed’s platform technology to assess skeletal muscle protein synthesis and muscle mass in Warfighters.

KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurod...
KineMed to Showcase Advances in Dynamic Proteomic Markers of Neurodegenerative Disease at the 8th Annual Neurodegenerative Conditions Research & Development Conference 
9/17/2014 1:00:00 AM

KineMed, Inc. announced today that Dr. Patrizia Fanara, Vice President of Neuroscience at KineMed, will give a presentation titled “Translatable Dynamic Biomarkers: The Future of Biomarkers in Neurodegenerative Diseases” at the 8th Annual Neurodegenerative Conditions Research & Development Conference. The presentation will take place on Friday, September 19th, from 12:55‐1:20 p.m. PDT at the Sheraton Fisherman's Wharf Hotel San Francisco, California as part of the session titled “Biomarkers: Translation from Discovery to Clinical.”

KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, ...
KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson’s Disease, and Diabetic Neuropathy
9/4/2014 1:00:00 AM

KineMed, Inc. today announced that the company has received a notice of allowance from the U.S. Patent and Trademark Office for the invention entitled: “Compositions and Methods of Treatment Using Modulators of Motoneuron Disease.” The patent allowance covers the treatment of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, Parkinson’s disease, and diabetic neuropathy using the microtubule target modulating agent, noscapine, alone or in combination with a variety of other agents.

Technology Highlight Video

Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer talks about the power of Proteome Dynamics at the Personalized Medicine World Conference 
Bookmark this page to: Add to Delicious  Add to LinkedIn  Add to Digg  Add to Reddit  Add to Yahoo Bookmarks  Add to Twitter  Add to Facebook  Add to StumbleUpon  Add to Google Bookmarks

5980 Horton Street | Suite 470 | Emeryville, CA 94608 | Tel.: USA [1] 510.655.6525 | Fax: [1] 510.655.6506 | TOLL-FREE: 855.KINEMED | E-mail: info@kinemed.com

 Copyright © 2013 KineMed, Inc.  |  All Rights Reserved  |  Privacy  |  Terms & Conditions